Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer

Peer Review reports

Original Submission
17 Mar 2009	Submitted	Original manuscript
17 Apr 2009	Reviewed	Reviewer Report - Stefan Kubicka
19 Apr 2009	Reviewed	Reviewer Report - Dirk Jaeger
14 May 2009	Reviewed	Reviewer Report - Carsten Nieder
29 Jun 2009	Author responded	Author comments - Sun Young Kim
Resubmission - Version 2
29 Jun 2009	Submitted	Manuscript version 2
8 Jul 2009	Reviewed	Reviewer Report - Carsten Nieder
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
21 Jul 2009	Editorially accepted
21 Jul 2009	Article published	10.1186/1471-2407-9-246

Back to article page